Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

TGFαL3-SEB fusion protein as an anticancer against ovarian cancer

Sat Mar 2 16:21:33 2024

(2020) TGFαL3-SEB fusion protein as an anticancer against ovarian cancer. European Journal of Pharmacology. ISSN 00142999 (ISSN)

Full text not available from this repository.

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

TGFαL3-SEB is a new synthetic fusion protein produced by the combination of the third loop of transforming growth factor with staphylococcal enterotoxin type B. In the current study, the anti-tumor effects of TGFαL3-SEB were evaluated against SKOV3 cells, which highly expressed the epidermal growth factor receptor (EGFR). Our findings showed that incubation of SKOV3 cells with 75, 100 and 150 μg/ml of TGFαL3-SEB significantly reduces the proliferation rate in a concentration-dependent manner (P < 0.05) and its IC50 value was 110 μg/ml. Caspase-3 activity was increased from 100 for control cells to 109, 144, and 169 for 75, 100 and 150 μg/ml of TGFαL3-SEB treatment, respectively. Caspase-9 activity and bax/bcl-2 ratio were also confirmed the apoptosis induction ability of TGFαL3-SEB (P < 0.001). Flow cytometry examination also showed that apoptosis was induced and the number of apoptotic cells was increased from 8.2 in un-treated cells to 20.9, 50, and 90 in response to 75, 100 and 150 μg/ml of TGFαL3-SEB fusion protein in a concentration-dependent manner (P < 0.05). The mRNA expression level of VEGF was also reduced to 0.89, 0.69, and 0.60, respectively in response to 75, 100 and 150 μg/ml of TGFαL3-SEB fusion protein exposure, respectively (P < 0.5). In summary, the findings of our study uncovered that TGFαL3-SEB fusion protein induced apoptosis and reduced angiogenesis in SKOV3 ovarian cancer cells in a concentration-dependent manner. This protein has the potential to act against EGFR expressing malignant cells to serve as a pro-apoptotic and angiogenesis blocker agents; however, further studies are needed to confirm its ability. © 2020

Item Type: Article
Creators:
CreatorsEmail
Maleki, F.UNSPECIFIED
Sadeghifard, N.UNSPECIFIED
Sedighian, H.UNSPECIFIED
Bakhtiyari, S.UNSPECIFIED
Hosseini, H. M.UNSPECIFIED
Fooladi, A. A. I.UNSPECIFIED
Keywords: Angiogenesis Apoptosis EGFR Necrosis Ovarian cancer TGFαL3-SEB fusion protein antineoplastic agent caspase 3 epidermal growth factor receptor fusion protein protein Bax protein bcl 2 third loop of transforming growth factor alpha Staphylococcal enterotoxin type B unclassified drug vasculotropin animal experiment animal model animal tissue antineoplastic activity Article Bagg albino mouse cancer cell culture cell proliferation cell viability controlled study drug cytotoxicity drug effect drug exposure drug screening embryo enzyme activation enzyme activity enzyme linked immunosorbent assay female flow cytometry human human cell IC50 mouse mRNA expression level MTT assay nonhuman ovary cancer priority journal protein expression protein targeting quantitative analysis real time polymerase chain reaction SK-OV-3 cell line
Divisions:
Journal or Publication Title: European Journal of Pharmacology
Journal Index: Scopus
Volume: 870
Identification Number: https://doi.org/10.1016/j.ejphar.2020.172919
ISSN: 00142999 (ISSN)
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/2844

Actions (login required)

View Item View Item